These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37962210)

  • 1. Abdominoplasty in a Patient With Type 3 von Willebrand Disease: A Case Report.
    Mert S; Kuhlmann C; Hagen CS; Kessler K; Balubaid M; Giunta RE; Wiggenhauser PS
    Ann Plast Surg; 2024 Jan; 92(1):133-136. PubMed ID: 37962210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful Perioperative Management of Orthotopic Cardiac Transplantation in a Pediatric Patient With Concurrent Congenital von Willebrand Disease and Acquired von Willebrand Syndrome Using Recombinant von Willebrand Factor.
    Batsuli G; Zimowski KL; Carroll R; White MH; Woods GM; Meeks SL; Sidonio RF
    J Cardiothorac Vasc Anesth; 2022 Mar; 36(3):724-727. PubMed ID: 33618961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in the therapy for von Willebrand disease].
    Nakayama T
    Rinsho Ketsueki; 2023; 64(5):389-396. PubMed ID: 37271530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of current perioperative management with Haemate
    Hazendonk HCAM; Heijdra JM; de Jager NCB; Veerman HC; Boender J; van Moort I; Mathôt RAA; Meijer K; Laros-van Gorkom BAP; Eikenboom J; Fijnvandraat K; Leebeek FWG; Cnossen MH;
    Haemophilia; 2018 May; 24(3):460-470. PubMed ID: 29573506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laboratory Testing for von Willebrand Factor: Factor VIII Binding (for 2N VWD).
    Mohammed S; Favaloro EJ
    Methods Mol Biol; 2017; 1646():461-472. PubMed ID: 28804848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Von Willebrand's disease: case report and review of literature.
    Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
    Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease.
    de Wee EM; Sanders YV; Mauser-Bunschoten EP; van der Bom JG; Degenaar-Dujardin ME; Eikenboom J; de Goede-Bolder A; Laros-van Gorkom BA; Meijer K; Hamulyák K; Nijziel MR; Fijnvandraat K; Leebeek FW;
    Thromb Haemost; 2012 Oct; 108(4):683-92. PubMed ID: 22918553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative management of patients with von Willebrand disease.
    O'Donnell JS; Lavin M
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):604-609. PubMed ID: 31808837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal von Willebrand factor secretion, factor VIII stabilization and thrombus dynamics in type 2N von Willebrand disease mice.
    Swystun LL; Georgescu I; Mewburn J; Deforest M; Nesbitt K; Hebert K; Dwyer C; Brown C; Notley C; Lillicrap D
    J Thromb Haemost; 2017 Aug; 15(8):1607-1619. PubMed ID: 28581694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report.
    Chikasawa Y; Hagiwara T; Bingo M; Amano K; Kikuchi S; Mitsuhashi A; Shinozawa K; Fukutake K; Kinai E
    Int J Hematol; 2022 Oct; 116(4):622-629. PubMed ID: 35532874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease.
    Gill JC; Shapiro A; Valentino LA; Bernstein J; Friedman C; Nichols WL; Manco-Johnson M
    Haemophilia; 2011 Nov; 17(6):895-905. PubMed ID: 21535320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a VWF/FVIII concentrate (wilate
    Srivastava A; Serban M; Werner S; Schwartz BA; Kessler CM;
    Haemophilia; 2017 Mar; 23(2):264-272. PubMed ID: 28026130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of emicizumab in von Willebrand disease (VWD) patients with and without alloantibodies to von Willebrand factor (VWF): Report of two cases and review of literature.
    Shanmukhaiah C; Jijina F; Kannan S; Pai NG; Kulkarni B; Khuba SV; Shaikh M; Joshi A; Phatale R; Apte S
    Haemophilia; 2022 Mar; 28(2):286-291. PubMed ID: 35014121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe Traumatic Brain Injury in a Patient with von Willebrand Disease Type 2A Successfully Treated with Factor VIII/von Willebrand Factor Concentrates: A Case Report.
    Koroki T; Abe T; Kamimura S; Ochiai H
    Am J Case Rep; 2022 Aug; 23():e936690. PubMed ID: 36040865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.
    Peyvandi F; Mamaev A; Wang JD; Stasyshyn O; Timofeeva M; Curry N; Cid AR; Yee TT; Kavakli K; Castaman G; Sytkowski A
    J Thromb Haemost; 2019 Jan; 17(1):52-62. PubMed ID: 30362288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of von Willebrand factor (recombinant) therapy for adult patients living with severe type 3 von Willebrand disease.
    Hancock JM; Escobar MA
    Expert Rev Hematol; 2023 Mar; 16(3):157-161. PubMed ID: 36861346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New advances in the diagnosis of von Willebrand disease.
    Sharma R; Haberichter SL
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):596-600. PubMed ID: 31808831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor VIII and von Willebrand factor changes after desmopressin and during pregnancy in type 2M von Willebrand disease Vicenza: a prospective study comparing patients with single (R1205H) and double (R1205H-M740I) defect.
    Castaman G; Federici AB; Bernardi M; Moroni B; Bertoncello K; Rodeghiero F
    J Thromb Haemost; 2006 Feb; 4(2):357-60. PubMed ID: 16420565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.